Khiron Life Sciences' Study: 80% Positively Respond To Cannabinoid Treatment For Chronic Pain And Other Conditions
A vertically integrated cannabis company Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC) announced Wednesday results from its first research study including 1,453 patients from Khiron-owned Zerenia Clinics.
